Abstract:The malignant transformation of normal cells is driven by both genetic and epigenetic changes. With the advent of next-generation sequencing and large-scale international consortia, it is now possible to profile the genomes and epigenomes of thousands of primary tumors from nearly every cancer type. These studies clearly demonstrate that the dynamic regulation of DNA methylation is a critical epigenetic mechanism of cancer initiation, maintenance, and progression. Proper control of DNA methylation is not only crucial for regulating gene transcription and tissue-specific cellular functions, but its broader consequences include maintaining the integrity of the genome and modulating the immune response. Here, we describe the aberrant DNA methylation changes in human cancers and how they contribute to the disease phenotypes. Aside from CpG island promoter DNA hypermethylation-based gene silencing, human cancers also display gene body DNA hypomethylation that is also associated with downregulated gene expression. In addition, the implementation of whole genome bisulfite sequencing (WGBS) has unveiled DNA hypomethylation of large blocks of the genome, known as partially methylated domains (PMDs), as well as cancer-specific DNA methylation aberrancies at enhancers and super-enhancers. Integrating WGBS and DNA methylation array data with mutation, copy number, and gene expression data has allowed for the identification of novel tumor suppressor genes and candidate driver genes of the disease state. Finally, we highlight potential clinical implications of these changes in the context of prognostic and diagnostic biomarkers, as well as therapeutic targets. Mounting evidence shows that DNA methylation data are effective and highly-sensitive disease classifiers, not only from analyses of the primary tumor but also from tumor-derived, cell free DNA (cfDNA) in blood of cancer patients. These findings highlight the power of DNA methylation aberrancies in providing efficacious biomarkers for clinical utility in improving patient diagnostics and their reversal using DNA methylation inhibitors in cancer treatment may be key in surveillance, treatment, and quality of life for cancer patients.

Data from Global Hypomethylation of Genomic DNA in Cancer-Associated Myofibroblasts

Supplementary Figure 1 from Global Hypomethylation of Genomic DNA in Cancer-Associated Myofibroblasts

Supplementary Figure 2 from Global Hypomethylation of Genomic DNA in Cancer-Associated Myofibroblasts

Genome-wide Screening of Aberrant DNA Methylation Which Associated with Gene Expression in Mouse Skin Cancers.

Supplementary Figure 3 from Global Hypomethylation of Genomic DNA in Cancer-Associated Myofibroblasts

Altered 5-Hydroxymethylcytosine Landscape in Primary Gastric Adenocarcinoma

Global DNA Hypomethylation Coupled to Repressive Chromatin Domain Formation and Gene Silencing in Breast Cancer.

Studies on the Hypomethylation of C-Myc, C-Ha-ras Oncogenes and Histopathological Changes in Human Gastric Carcinoma.

Analysis of DNA Methylation Patterns Associated with the Gastric Cancer Genome.

The Role of DNA Methylation and DNA Methyltransferases in Cancer

Hypermethylation Of The Hmlh1 Gene Promoter In Human Gastric Cancers With Microsatellite Instability

Hypermethylation of the GATA gene family in esophageal cancer

Oncogenic roles of DNA hypomethylation through the activation of cancer-germline genes

Data from DNA Hypomethylation and Ovarian Cancer Biology

Hypermethylated DNA as potential biomarkers for gastric cancer diagnosis.

Methylation Ofgata-4Andgata-5and Development of Sporadic Gastric Carcinomas

SMYD5 methylation of rpL40 links ribosomal output to gastric cancer

Alteration of DNA methylation in gastrointestinal carcinogenesis.

The prognostic value of global DNA hypomethylation in cancer: a meta-analysis.

Apposition of fibroblasts with metaplastic gastric cells promotes dysplastic transition

DNA methylation profiling identifies epigenetic signatures of early gastric cancer